TILS | Jotup

CGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United States

Retrieved on:

星期四, 九月 21, 2023

GMP, Partnership, CGT, Health care, Research, Cell, Hospital, Patient, TILS, Leukapheresis, R, Health, Fausto Pocar, Pharmaceutical industry, Medical device

The two companies are collaborating to leverage CGT Global’s extensive network of CGT Clinics and Healthcare partnerships to expand commercialization of CGTs in California and other US locations.

Key Points:

The two companies are collaborating to leverage CGT Global’s extensive network of CGT Clinics and Healthcare partnerships to expand commercialization of CGTs in California and other US locations.
Resources will be aligned to place technology-agnostic Octomera Mobile Processing Units & Labs (OMPULs) for leukapheresis and the production of CAR-T and TILS products.
The Company expects the footprint to grow as CGT Global partners with 32 hospitals today and anticipates partnering with over 200 hospitals by the end of 2024.
CGT Global has created a bicoastal network of CGT Clinics in the US using state-of-the-art technology and specialized training in leukapheresis.

Biocytogen Officially Launches RenMice® Series

Retrieved on:

星期五, 九月 15, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) officially announces the RenMice® series, which includes a collection of independently developed, fully human antibody mice and TCR mice with proprietary intellectual property.

Key Points:

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) officially announces the RenMice® series, which includes a collection of independently developed, fully human antibody mice and TCR mice with proprietary intellectual property.
The RenMice® series encompasses five strains of fully human antibody/TCR mice: RenMab™, RenLite®, RenNano®, RenTCR™, and RenTCR-mimic™.
View the full release here: https://www.businesswire.com/news/home/20230915794363/en/
RenMice Series and Their Drug Discovery Applications (Graphic: Business Wire)
Since their successive release in 2019, Biocytogen’s RenMice series has received global recognition in the biopharmaceutical and biotechnology field.
As of June 30, 2023, Biocytogen has entered into RenMice licensing agreements with 20 biopharmaceutical/biotechnology companies worldwide; 42 target-nominated antibody development projects have been initiated.

Biocytogen Officially Launches RenMice® Series

Retrieved on:

星期五, 九月 15, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) officially announces the RenMice® series, which includes a collection of independently developed, fully human antibody mice and TCR mice with proprietary intellectual property.

Key Points:

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) officially announces the RenMice® series, which includes a collection of independently developed, fully human antibody mice and TCR mice with proprietary intellectual property.
The RenMice® series encompasses five strains of fully human antibody/TCR mice: RenMab™, RenLite®, RenNano®, RenTCR™, and RenTCR-mimic™.
View the full release here: https://www.businesswire.com/news/home/20230914583107/en/
RenMice Series and Their Drug Discovery Applications (Graphic: Business Wire)
Since their successive release in 2019, Biocytogen’s RenMice series has received global recognition in the biopharmaceutical and biotechnology field.
As of June 30, 2023, Biocytogen has entered into RenMice licensing agreements with 20 biopharmaceutical/biotechnology companies worldwide; 42 target-nominated antibody development projects have been initiated.

Ibex Launches Galen™ Breast HER2, Supporting Improved Biomarker Scoring in Breast Cancer Patients

Retrieved on:

星期四, 九月 7, 2023

TEL AVIV, Israel, Sept. 7, 2023 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced the launch of Galen™ Breast HER2, an AI-powered solution that aids pathologists in setting a higher standard for accurate and reproducible HER2 (human epidermal growth factor receptor 2) scoring in breast cancer patients.

Key Points:

HER2, one of the proteins responsible for division and proliferation of breast cancer cells, is expressed in many breast tumors and its accurate assessment is critical for identifying patients who are likely to benefit from HER2-directed therapies.
Traditionally, pathologists evaluate HER2 in tumor samples visually, which may result in varied interpretations as scoring is semi-quantitative and thus somewhat subjective1.
Galen Breast HER2 was developed and validated by Ibex in collaboration with AstraZeneca and Daiichi Sankyo .
Information about Galen Breast HER2 and Galen Breast will be available at the 35th European Congress of Pathology in Dublin, Ireland, between September 9-13 (Ibex Medical Analytics - booth number 23).

Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support

Retrieved on:

星期三, 九月 6, 2023

Children's Hospital Los Angeles, GMP, University of California, Davis, Bauer, University, HIV, Child, Washington University in St. Louis, Johns Hopkins University, UC, Patient, CGT, Engineering, University of Southern California academics, Cell, TILS, ADA, Fausto Pocar, Pharmaceutical industry

“Gerhard is an industry pioneer with unmatched expertise.

Key Points:

“Gerhard is an industry pioneer with unmatched expertise.
He began his time at Johns Hopkins University where he was part of the team that developed the first stem cell gene therapy for HIV.
“We all understand that the old methods of cell and gene therapy development and production no longer apply.
At Octomera, we have the network, applied experience, and passion to support drug developers as they develop and commercialize lifesaving medicines,” said Mr. Bauer.

Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on:

星期五, 九月 1, 2023

The shares began trading on the Nasdaq Global Market on July 21, 2023, under the ticker symbol “TSBX”.

Key Points:

The shares began trading on the Nasdaq Global Market on July 21, 2023, under the ticker symbol “TSBX”.
Cash, Cash Equivalents and Short-Term Investments: As of June 30, 2023, cash, cash equivalents and short-term investments were $49.2 million.
The Company expects that the combined cash, cash equivalents and short-term investments will be sufficient to fund its operations into the second quarter of 2025.
Net Loss: Net loss for the three months ended June 30, 2023, was $21.5 million, compared to net income of $11.6 million for the second quarter of 2022.

Aichi Cancer Center and NEC Develop an Efficient Method for Identifying Lung Cancer Antigens and Antigen-Specific T Cells

Retrieved on:

星期二, 八月 8, 2023

- Aichi Cancer Center and NEC developed a method for efficiently identifying lung cancer antigens (oncology marks) and antigen-specific T cells by combining single-cell analysis (1) of Tumor Infiltrating Lymphocytes (TIL) and NEC's AI-based antigen prediction system.

Key Points:

- Aichi Cancer Center and NEC developed a method for efficiently identifying lung cancer antigens (oncology marks) and antigen-specific T cells by combining single-cell analysis (1) of Tumor Infiltrating Lymphocytes (TIL) and NEC's AI-based antigen prediction system.
- Aichi Cancer Center and NEC clarified the characteristics of T cells that specifically recognize antigens.
In collaboration with NEC and leading research institutes, the Aichi Cancer Center has developed a procedure for efficiently identifying antigens and antigen-specific T cells using surgical samples from patients with cancer.
(2) KK-LC-1 (KitaKyushu Lung Canner antigen-1): Cancer and testis antigens that have been reported to be expressed in cancer.

NOG Provides Update on 2023 Guidance and Preliminary Second Quarter Financial and Operational Update

Retrieved on:

星期三, 七月 26, 2023

Oil, Gas, Energy, Well, Permian, TIL, NOG, MPDC, G&A, Public expenditure, Forge, TILS, Acquisition, DD, Growth, Boe, Curtailment (electricity), Airline, Video game, Risk management, Mascot

Production from the Forge and Novo acquisitions are reflected in the updated 2023 guidance, based on June 30 and August 15 (estimated) closings, respectively.

Key Points:

Production from the Forge and Novo acquisitions are reflected in the updated 2023 guidance, based on June 30 and August 15 (estimated) closings, respectively.
The Company and its operating partners are adjusting 2023 activity and shifting select development into late 2023 and early 2024.
A portion of TIL deferrals relate to the Mascot project, where NOG and its partner have modified the completion schedule.
NOG expects capital expenditures for the second half of 2023 to be equally weighted by quarter.

Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference

Retrieved on:

星期一, 六月 26, 2023

Society, MBBS, Gene, TIL, Cancer, Ovary, NSCLC, Lung cancer, Doctor of Philosophy, Trial of the century, TCR, TILS, Costar, Patient, Melanoma, Carcinoma, Cell, Conference, Medical imaging, DALLAS

DALLAS, June 26, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported an oral presentation at the British Society for Gene and Cell Therapy Annual Conference, demonstrating that its proprietary CoStimulatory Antigen Receptor (CoStAR) platform enhances activity of TILs against autologous tumor.

Key Points:

The presentation highlighted CoStAR’s unique mechanism of action which results in greatly enhanced activity of TILs when activation occurs through both the native TCR and engineered CoStAR receptors.
Additionally, novel data demonstrated that Instil’s FRα-CoStAR enhances activity of TILs against autologous tumors with varied expression of FRα including ovarian, renal, and non-small cell lung cancer tumors.
The robust activity of NSCLC, ovarian, and renal carcinoma CoStAR-TILs against autologous tumor exceeded that of genetically unmodified melanoma TILs, as measured by secretion of IFNγ.
“These preclinical data continue to support our excitement around the anticipated resumption of the clinical study of ITIL-306 in patients with advanced cancers which express FRα.”

Global Breast Cancer Immunotherapy Market & Clinical Trials Forecast to 2028 - ResearchAndMarkets.com

Retrieved on:

星期一, 六月 19, 2023

The "Global Breast Cancer Immunotherapy Market & Clinical Trials Forecast 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Global Breast Cancer Immunotherapy Market & Clinical Trials Forecast 2028" report has been added to ResearchAndMarkets.com's offering.
The introduction of immunotherapy, particularly immune checkpoint inhibitors has transformed the treatment for breast cancer, with immunotherapy being effective even in aggressive forms of breast cancer such as triple-negative breast cancer.
It can be said that immune checkpoint inhibitors have been a vital factor that has resulted in the growing market of breast cancer immunotherapy.
Additionally, moving beyond immune checkpoint inhibitors, the market of breast cancer immunotherapy is also witnessing a rise in novel treatment approaches.